Targeting MuRF1 by small molecules in a HFpEF rat model improves myocardial diastolic function and skeletal muscle contractility - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35301823/
doi: 10.1002/jcsm.12968. Online ahead of print. 1 Laboratory of Molecular and Experimental Cardiology, TU Dresden, Heart Center Dresden, Dresden, Germany. 2 Dresden Cardiovascular Research Institute and Core Laboratories GmbH, Dresden,...
Conclusions: MyoMed-205 improved myocardial diastolic function and prevented SKM atrophy/function in the ZSF1 animal model of HFpEF. Mechanistically, SKM benefited from an attenuated ubiquitin proteasome system and augmented synthesis/activity of proteins of the mitochondrial respiratory chain while the myocardium seemed to benefit from...
Empagliflozin and decreased risk of nephrolithiasis: A potential new role for SGLT2 inhibition? - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35290464/
Compared to placebo, empagliflozin therapy was associated with an approximate 40% reduced risk of urinary tract stone events in T2D patients. The underlying mechanisms are unknown but may involve altered...
Conclusion: Compared to placebo, empagliflozin therapy was associated with an approximate 40% reduced risk of urinary tract stone events in T2D patients. The underlying mechanisms are unknown but may involve altered lithogenic profile of the urine. Dedicated randomized prospective clinical trials are warranted to confirm these initial...
Sodium-Glucose Cotransporter 2 Inhibitors and Cardiac Remodeling - PubMed
Source : https://pubmed.ncbi.nlm.nih.gov/35290593/
Sodium-glucose cotransporter 2 (SGLT2) inhibitors have evident cardiovascular benefits in patients with type 2 diabetes with or at high risk for atherosclerotic cardiovascular disease, heart failure with reduced ejection fraction,...
Conclusions/Relevance: Cardiac remodeling encompasses molecular, cellular, and interstitial changes that result in favorable changes in the mass, geometry, size, and function of the heart. The pathophysiological mechanisms of adverse cardiac remodeling are related to increased apoptosis and necrosis, decreased autophagy, impairments of...
Empagliflozin Inhibits Hepatic Gluconeogenesis and Increases Glycogen Synthesis by AMPK/CREB/GSK3β Signalling Pathway
Source : https://www.frontiersin.org/articles/10.3389/fphys.2022.817542/full
Increases in glucose production and decreases in hepatic glycogen storage induce glucose metabolic abnormalities in type 2 diabetes (T2DM). Empagliflozin, a sodium-dependent glucose transporter 2 (SGLT2) inhibitor, is an effective...
Conclusions: The results of the 5-Aminoimidazole-4-carboxamide1-β-D-ribofuranoside (AIACR) intervention in HL7702 cells were consistent with those of empagliflozin treatment, and the effects of empagliflozin were abolished by compound C. In summary, empagliflozin could maintain glucose homoeostasis by reducing gluconeogenesis and increasing...
Automated Insulin Delivery (AID) with SGLT2i Combination Therapy in Type 1 Diabetes
Source : https://www.liebertpub.com/doi/10.1089/dia.2021.0542
Use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) as adjunct therapy to insulin in type 1 diabetes (T1D) has been previously studied. In this study, we present data from the first...
Conclusion/Relevance: Interpretation In an eight-week outpatient study, addition of 5 mg daily empagliflozin to commercially available AID or PLGS systems significantly improved daytime glucose control in individuals with T1D, without increased hypoglycaemia risk. However, the risk of ketosis and ketoacidosis remains. Therefore, future studies...